Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acefyl is a brand of bronchodilator medications developed and manufactured by Nabiqasim Industries, primarily containing **acepifylline** (acefylline piperazine). Acepifylline is a xanthine derivative related to theophylline that acts as a bronchodilator and respiratory stimulant. Its primary mechanism of action involves the non-selective inhibition of phosphodiesterase (PDE) enzymes, which leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels, resulting in the relaxation of bronchial smooth muscle. Additionally, it acts as an adenosine receptor antagonist. Acefyl is indicated for the symptomatic treatment of respiratory disorders associated with bronchospasm, such as bronchial asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). The product line includes a single-agent formulation (Acefyl 125) and a multi-ingredient expectorant variant (Acefyl Cough) which contains additional components like diphenhydramine and ammonium chloride.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acepifylline.